AXS-12 (Reboxetine)

Drug identity checked against registry records

Also recorded as AXS-12; Reboxetine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)NCT03881852AXSMPhase 2Completed2019-11-27Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.